Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our customタンパク質 services!
カスタムサービスについてのお問い合わせはこちら >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| OX40 mAb - 01 | Lead | AutoImmunity | Autoimmune disease |
Expression analysis of human OX40 on Human OX40 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human OX40 (Luc) HEK293 Reporter Cell or negative control cell using biotinylated human OX40 ligand protein followed by staining with Streptavidin-PE.
FACS assay shows that Biotinylated Human OX40 Ligand, Avitag,Fc Tag (OXL-H82F4) can bind to HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line(HEK-ATP053). HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SAR-442970 | SAR-442970 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| SHR-1806 | SHR-1806 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
| KN-052 | KN-052 | Phase 1 Clinical | Solid tumours | Details | |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Neoplasms | Details | |
| Tavolimab | MEDI-0562 | Phase 1 Clinical | Medimmune | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc | Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
| Telazorlimab | GBR-830; ISB-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Dermatitis, Atopic | Details |
| HFB-3010(HiFiBiO Therapeutics) | HFB-3010; HFB-301001 | Phase 1 Clinical | HiFiBiO Therapeutics | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular | Details |
| INBRX-106 | ES-102; ES102; INBRX-106 | Phase 1 Clinical | Inhibrx | Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| BAT-6026 | BAT-6026 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd, Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| Revdofilimab | ABBV-368; PR-1628103 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
| Cudarolimab | IBI-101 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasms; Neoplasm Metastasis | Details |
| GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Neoplasms; Multiple Myeloma | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | Details |
| INCAGN-1949 | INCAGN-1949 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Solid tumours; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
| BMS-986178 | BMS-986178 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| IMG-007 | IMG-007 | Phase 1 Clinical | Hutchmed (China) Ltd | Dermatitis, Atopic | Details |
| Ivuxolimab | PF-8600; PF-04518600 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
| MEDI-6469 | MEDI-6469; AGX-051 | Phase 1 Clinical | Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma | Details |
| Rocatinlimab | KHK-4083; AMG-451 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd, Amgen Inc | Abdominal Pain; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Digestive System Diseases; Autoimmune Diseases; Colitis; Colonic Diseases; Colitis, Ulcerative; Dermatitis, Atopic; Intestinal Diseases | Details |
| BGB-A445 | BGB-A445 | Phase 2 Clinical | Beigene Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) | YH-002 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
